| NCT ID | NCT07597837 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tufts Medical Center |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2026-02-26 |
| Primary Completion | 2045-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2026-02-26 with a primary completion date of 2045-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a retrospective and prospective chart review of surgical outcomes and collecting patient satisfaction outcomes using validated surveys for oncoplastic breast surgery and Goldilocks mastectomy.
Eligibility Criteria
Inclusion Criteria: * Biological females \>= 18 years old requiring oncologic breast surgery with and without reconstruction at Tufts Medicine. Exclusion Criteria: * Biological females \< 18 years old
Frequently Asked Questions
Who can join the NCT07597837 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07597837 currently recruiting?
Yes, NCT07597837 is actively recruiting participants. Visit ClinicalTrials.gov or contact Tufts Medical Center to inquire about joining.
Where is the NCT07597837 trial being conducted?
This trial is being conducted at Boston, United States, Melrose, United States.
Who is sponsoring the NCT07597837 clinical trial?
NCT07597837 is sponsored by Tufts Medical Center. The trial plans to enroll 1,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.